Sr.
No. |
Particulars |
Quarter
Ended
31.12.2007
(Unaudited)
|
Corresponding
Quarter Ended
31.12.2006
(Unaudited)
|
Year
Ended
30.09.2007
18 Months (Audited) |
1.
|
Gross
Sales |
2381 |
2463 |
14983 |
| . |
Less:
Excise Duty |
135 |
110 |
812 |
| . |
Net
Sales |
2246 |
2352 |
14171 |
| 2. |
Other
Income |
161 |
(43) |
393 |
|
Total
Income |
2406 |
2309 |
14563 |
| 3. |
Total
Expenditure |
2253 |
2653 |
16962 |
| . |
a)
(Increase) / Decrease in Stock in
Trade |
(236) |
(257) |
2427
|
| . |
b)
Material Consumed |
1604 |
2202 |
9513 |
| . |
c)
Employee Cost |
292 |
270 |
1704 |
| . |
d)
Operational and Administrative Expenses |
592 |
438 |
3318 |
| 4. |
Profit / (Loss) before Interest, Depreciation and Tax |
154 |
(344) |
(2398) |
| 5. |
Finance Cost
(Net) |
199 |
274 |
1145 |
| 6. |
Profit
/ (Loss) after Interest, but before Depreciation and Tax |
(46) |
(618) |
(3543) |
| 7. |
Depreciation |
348 |
355 |
2123 |
| 8. |
Profit
/ (Loss) before Tax |
(394) |
(973) |
(5666) |
| 9. |
Provision
for Fringe benefit Tax |
4 |
10 |
25 |
| 10. |
Profit / (Loss) after Tax and before extra ordinary item |
(398) |
(983) |
(5691) |
| 11. |
Extraordinary Items (Net) |
1055 |
0 |
0 |
| 12. |
Profit
/ (Loss) for the Period |
657 |
(983) |
(5691) |
| 13. |
Paid
up Equity Share Capital (Face Value Rs.10/- each) |
1055 |
3225 |
3349 |
| 14. |
Reserves
excluding Revaluation Reserves |
--- |
--- |
4770 |
| 15. |
EPS for
the period, for the year to date and for the Previous year |
--- |
--- |
--- |
| . |
a) Before Extraordinary item Basic
(Rs.) |
(1.21) |
(3.11) |
(17.14) |
| . |
b) After Extraordinary item Basic
(Rs.) |
1.94 |
(1.93) |
(15.65) |
| 16. |
Aggregate of Non-Promoters Shareholding: |
. |
. |
. |
| . |
Number of Shares
Percentage of Shareholdings |
22966528
68.58%
|
22803528
70.72%
|
22966528
68.58% |
Notes
:
1. The above results reviewed by the Audit Committee
and taken on record by the Board of Directors of the Company at its meeting held
on 31st January,
2008.
2. Previous period
figures have been regrouped / rearranged, wherever
necessary to confirm to the current period's classification.
3. Extraordinary items represent Loans written
back on One-Time settlement with lenders net of expenses.
4.
Auditor's observation:
Investments and Advances made to Subsidiary Company, Kopran Research
Laboratories Ltd. amounting to Rs.6504.77 Lacs and Joint Venture,
Globalpharma Co. LLC amounting to Rs.1196.56 Lacs
which in the opinion of the Auditors are doubtful. In the opinion of the
Management since
the Subsidiary Company, Kopran Research
Laboratories Ltd is proposed to be merged and investments in Joint Venture,
Global Pharma Co. LLC
are made for long term period hence no provision
is required to be made.
5. The company received 7 complaints from the
shareholders during the quarter ended December, 2007 and they were resolved.
For and on behalf of the Board of
Director...s
Susheel
G.
Somani
Chairman
Place: Mumbai
Date : 31st January, 2008
______________________________________________________________________
For more detail information, Contact
us.
